Theravance Biopharma, Inc. (NASDAQ:TBPH – Get Free Report) has been assigned an average recommendation of “Hold” from the seven research firms that are presently covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a hold recommendation. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $19.00.
A number of analysts have recently issued reports on the stock. Zacks Research cut shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 7th. Weiss Ratings upgraded shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday, August 17th. Finally, BTIG Research dropped coverage on shares of Theravance Biopharma in a report on Thursday, September 24th. They issued a “neutral” rating for the company.
View Our Latest Stock Report on Theravance Biopharma
Insider Buying and Selling
In other Theravance Biopharma news, SVP Rhonda Farnum sold 13,314 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $17.03, for a total transaction of $226,737.42. Following the sale, the senior vice president directly owned 213,476 shares of the company’s stock, valued at $3,635,496.28. This trade represents a 5.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.65% of the stock is currently owned by corporate insiders.
Institutional Trading of Theravance Biopharma
Several institutional investors have recently made changes to their positions in TBPH. Allspring Global Investments Holdings LLC bought a new stake in Theravance Biopharma during the 1st quarter valued at approximately $171,000. Globeflex Capital L P purchased a new position in Theravance Biopharma in the 1st quarter worth approximately $171,000. Financiere des Professionnels Fonds d investissement inc. purchased a new position in Theravance Biopharma in the 1st quarter worth approximately $268,000. Quantinno Capital Management LP lifted its holdings in Theravance Biopharma by 32.9% in the 1st quarter. Quantinno Capital Management LP now owns 18,038 shares of the biopharmaceutical company’s stock worth $293,000 after purchasing an additional 4,463 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new position in Theravance Biopharma in the 2nd quarter worth approximately $302,000. Hedge funds and other institutional investors own 99.10% of the company’s stock.
Theravance Biopharma Stock Performance
NASDAQ TBPH opened at $17.03 on Wednesday. Theravance Biopharma has a 12 month low of $13.08 and a 12 month high of $21.03. The stock has a market cap of $884.18 million, a price-to-earnings ratio of 16.86 and a beta of 0.25. The company’s 50 day moving average is $17.03 and its two-hundred day moving average is $16.89.
Theravance Biopharma (NASDAQ:TBPH – Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.18). The firm had revenue of $20.73 million for the quarter, compared to analysts’ expectations of $22.49 million. Theravance Biopharma had a net margin of 51.58% and a negative return on equity of 0.77%. Sell-side analysts forecast that Theravance Biopharma will post 1.56 EPS for the current year.
Theravance Biopharma Company Profile
Theravance Biopharma is a biopharmaceutical company focused on developing and commercializing medicines. Its marketed product, YUPELRI (revefenacin), is a once-daily nebulized treatment for the maintenance of chronic obstructive pulmonary disease (COPD) in adults. In the United States, the product is commercialized through a collaboration with Viatris. The company was established as an independent business following its separation from Theravance, Inc. in 2014. Its research and development work has included therapies for respiratory and other serious conditions.
Featured Stories
- Five stocks we like better than Theravance Biopharma
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
